BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25040181)

  • 1. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.
    Lin K; Farahani M; Yang Y; Johnson GG; Oates M; Atherton M; Douglas A; Kalakonda N; Pettitt AR
    Br J Haematol; 2014 Nov; 167(3):346-55. PubMed ID: 25040181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.
    Ouillette P; Erba H; Kujawski L; Kaminski M; Shedden K; Malek SN
    Cancer Res; 2008 Feb; 68(4):1012-21. PubMed ID: 18281475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions.
    Tolomeo D; Agostini A; Solimando AG; Cunsolo CL; Cimarosto L; Palumbo O; Palumbo P; Carella M; Hernández-Sánchez M; Hernández-Rivas JM; Storlazzi CT
    Cancer Genet; 2023 Apr; 272-273():16-22. PubMed ID: 36641997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia.
    Lehmann S; Ogawa S; Raynaud SD; Sanada M; Nannya Y; Ticchioni M; Bastard C; Kawamata N; Koeffler HP
    Cancer; 2008 Mar; 112(6):1296-305. PubMed ID: 18246537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
    Fabbri M; Bottoni A; Shimizu M; Spizzo R; Nicoloso MS; Rossi S; Barbarotto E; Cimmino A; Adair B; Wojcik SE; Valeri N; Calore F; Sampath D; Fanini F; Vannini I; Musuraca G; Dell'Aquila M; Alder H; Davuluri RV; Rassenti LZ; Negrini M; Nakamura T; Amadori D; Kay NE; Rai KR; Keating MJ; Kipps TJ; Calin GA; Croce CM
    JAMA; 2011 Jan; 305(1):59-67. PubMed ID: 21205967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.
    Dijkstra MK; van Lom K; Tielemans D; Elstrodt F; Langerak AW; van 't Veer MB; Jongen-Lavrencic M
    Leukemia; 2009 Mar; 23(3):625-7. PubMed ID: 18818704
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
    Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
    Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.
    Bacalini MG; Tavolaro S; Peragine N; Marinelli M; Santangelo S; Del Giudice I; Mauro FR; Di Maio V; Ricciardi MR; Caiafa P; Chiaretti S; Foà R; Guarini A; Reale A
    Exp Hematol; 2012 Mar; 40(3):197-206.e1. PubMed ID: 22120020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
    Calin GA; Dumitru CD; Shimizu M; Bichi R; Zupo S; Noch E; Aldler H; Rattan S; Keating M; Rai K; Rassenti L; Kipps T; Negrini M; Bullrich F; Croce CM
    Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15524-9. PubMed ID: 12434020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.
    Leventaki V; Rodic V; Tripp SR; Bayerl MG; Perkins SL; Barnette P; Schiffman JD; Miles RR
    Br J Haematol; 2012 Sep; 158(6):763-71. PubMed ID: 22845047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
    Chang H; Jiang AM; Qi CX
    Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia.
    Migliazza A; Bosch F; Komatsu H; Cayanis E; Martinotti S; Toniato E; Guccione E; Qu X; Chien M; Murty VV; Gaidano G; Inghirami G; Zhang P; Fischer S; Kalachikov SM; Russo J; Edelman I; Efstratiadis A; Dalla-Favera R
    Blood; 2001 Apr; 97(7):2098-104. PubMed ID: 11264177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene dosage effects in chronic lymphocytic leukemia.
    Sellmann L; Scholtysik R; Kreuz M; Cyrull S; Tiacci E; Stanelle J; Carpinteiro A; Nückel H; Boes T; Gesk S; Siebert R; Klein-Hitpass L; Dührsen U; Dürig J; Küppers R
    Cancer Genet Cytogenet; 2010 Dec; 203(2):149-60. PubMed ID: 21156227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rb1 gene expression in B-cell lymphocytic leukaemia cases with deletion in the 13q14 region.
    Antosz H; Kitlińska J; Kwiatkowska-Drabik B; Koczkodaj D; Wach M; Antosz M; Rudzki S; Wojcierowski J
    Cytobios; 1997; 92(369):111-21. PubMed ID: 9693880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
    Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
    Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.
    Mohr J; Helfrich H; Fuge M; Eldering E; Bühler A; Winkler D; Volden M; Kater AP; Mertens D; Te Raa D; Döhner H; Stilgenbauer S; Zenz T
    Blood; 2011 Feb; 117(5):1622-32. PubMed ID: 21115975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (TP53, p21(CDKN1A), BCL2 and BAX) with respect to occupational exposure to styrene.
    Hanova M; Vodickova L; Vaclavikova R; Smerhovsky Z; Stetina R; Hlavac P; Naccarati A; Slyskova J; Polakova V; Soucek P; Kumar R; Hemminki K; Vodicka P
    Carcinogenesis; 2011 Jan; 32(1):74-9. PubMed ID: 20966084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia.
    Fink SR; Smoley SA; Stockero KJ; Paternoster SF; Thorland EC; Van Dyke DL; Shanafelt TD; Zent CS; Call TG; Kay NE; Dewald GW
    Cancer Genet Cytogenet; 2006 Jun; 167(2):177-81. PubMed ID: 16737921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.